vs
Nurix Therapeutics, Inc.（NRIX）与Rocky Mountain Chocolate Factory, Inc.（RMCF）财务数据对比。点击上方公司名可切换其他公司
Nurix Therapeutics, Inc.的季度营收约是Rocky Mountain Chocolate Factory, Inc.的1.8倍（$13.6M vs $7.5M），Rocky Mountain Chocolate Factory, Inc.净利率更高（-2.1% vs -576.1%，领先574.1%），Nurix Therapeutics, Inc.同比增速更快（2.2% vs -4.4%），Rocky Mountain Chocolate Factory, Inc.自由现金流更多（$-1.3M vs $-73.0M），过去两年Rocky Mountain Chocolate Factory, Inc.的营收复合增速更高（1.9% vs -9.5%）
Nurix Therapeutics是一家临床阶段生物制药企业，专注于发现、开发及商业化针对癌症、免疫疾病等存在重大未满足医疗需求的新型靶向蛋白降解疗法，依托专有的E3泛素连接酶调节技术推进管线研发，与全球多家制药企业达成合作。
落基山巧克力厂是美国知名巧克力企业，同时开展国际特许经营业务，集糖果生产与零售运营于一体，总部位于美国科罗拉多州杜兰戈，除美国本土门店外，在巴拿马、菲律宾也设有经营网点。
NRIX vs RMCF — 直观对比
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $13.6M | $7.5M |
| 净利润 | $-78.2M | $-155.0K |
| 毛利率 | — | 34.0% |
| 营业利润率 | -612.0% | 1.1% |
| 净利率 | -576.1% | -2.1% |
| 营收同比 | 2.2% | -4.4% |
| 净利润同比 | -33.6% | 81.7% |
| 每股收益（稀释后） | $-0.83 | $-0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $13.6M | $7.5M | ||
| Q3 25 | $7.9M | $6.8M | ||
| Q2 25 | $44.1M | $6.4M | ||
| Q1 25 | $18.5M | $8.9M | ||
| Q4 24 | $13.3M | $7.9M | ||
| Q3 24 | $12.6M | $6.4M | ||
| Q2 24 | $12.1M | $6.4M | ||
| Q1 24 | $16.6M | $7.3M |
| Q4 25 | $-78.2M | $-155.0K | ||
| Q3 25 | $-86.4M | $-662.0K | ||
| Q2 25 | $-43.5M | $-324.0K | ||
| Q1 25 | $-56.4M | $-2.9M | ||
| Q4 24 | $-58.5M | $-847.0K | ||
| Q3 24 | $-49.0M | $-722.0K | ||
| Q2 24 | $-44.5M | $-1.7M | ||
| Q1 24 | $-41.5M | $-1.6M |
| Q4 25 | — | 34.0% | ||
| Q3 25 | — | 23.6% | ||
| Q2 25 | — | 31.1% | ||
| Q1 25 | — | 10.8% | ||
| Q4 24 | — | 23.4% | ||
| Q3 24 | — | 31.8% | ||
| Q2 24 | — | 12.8% | ||
| Q1 24 | — | 24.3% |
| Q4 25 | -612.0% | 1.1% | ||
| Q3 25 | -1157.7% | -7.0% | ||
| Q2 25 | -109.7% | -2.3% | ||
| Q1 25 | -340.7% | -30.3% | ||
| Q4 24 | -486.7% | -8.9% | ||
| Q3 24 | -433.8% | -14.3% | ||
| Q2 24 | -401.4% | -25.4% | ||
| Q1 24 | -272.6% | -21.7% |
| Q4 25 | -576.1% | -2.1% | ||
| Q3 25 | -1094.8% | -9.7% | ||
| Q2 25 | -98.7% | -5.1% | ||
| Q1 25 | -305.4% | -32.5% | ||
| Q4 24 | -440.7% | -10.7% | ||
| Q3 24 | -388.9% | -11.3% | ||
| Q2 24 | -368.4% | -25.9% | ||
| Q1 24 | -250.3% | -21.9% |
| Q4 25 | $-0.83 | $-0.02 | ||
| Q3 25 | $-1.03 | $-0.09 | ||
| Q2 25 | $-0.52 | $-0.04 | ||
| Q1 25 | $-0.67 | $-0.38 | ||
| Q4 24 | $-0.74 | $-0.11 | ||
| Q3 24 | $-0.67 | $-0.11 | ||
| Q2 24 | $-0.71 | $-0.26 | ||
| Q1 24 | $-0.76 | $-0.25 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $247.0M | $641.0K |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $538.7M | $6.0M |
| 总资产 | $688.1M | $20.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $247.0M | $641.0K | ||
| Q3 25 | $78.4M | $2.0M | ||
| Q2 25 | $84.3M | $893.0K | ||
| Q1 25 | $75.9M | $720.0K | ||
| Q4 24 | $110.0M | $1.1M | ||
| Q3 24 | $99.0M | $973.0K | ||
| Q2 24 | $116.8M | $637.0K | ||
| Q1 24 | $49.8M | $2.1M |
| Q4 25 | $538.7M | $6.0M | ||
| Q3 25 | $372.3M | $6.1M | ||
| Q2 25 | $447.6M | $6.7M | ||
| Q1 25 | $480.9M | $7.0M | ||
| Q4 24 | $527.0M | $9.8M | ||
| Q3 24 | $376.9M | $10.5M | ||
| Q2 24 | $370.7M | $9.0M | ||
| Q1 24 | $168.7M | $10.6M |
| Q4 25 | $688.1M | $20.7M | ||
| Q3 25 | $522.5M | $22.3M | ||
| Q2 25 | $591.6M | $20.1M | ||
| Q1 25 | $615.0M | $21.2M | ||
| Q4 24 | $669.3M | $21.6M | ||
| Q3 24 | $513.6M | $21.1M | ||
| Q2 24 | $511.0M | $19.0M | ||
| Q1 24 | $312.7M | $20.6M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-67.8M | $-1.2M |
| 自由现金流经营现金流 - 资本支出 | $-73.0M | $-1.3M |
| 自由现金流率自由现金流/营收 | -537.4% | -16.9% |
| 资本支出强度资本支出/营收 | 37.8% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-263.5M | — |
8季度趋势，按日历期对齐
| Q4 25 | $-67.8M | $-1.2M | ||
| Q3 25 | $-57.4M | $-488.0K | ||
| Q2 25 | $-63.2M | $350.0K | ||
| Q1 25 | $-61.1M | $1.2M | ||
| Q4 24 | $-48.8M | $-2.1M | ||
| Q3 24 | $-42.2M | $-3.5M | ||
| Q2 24 | $-39.7M | $-2.2M | ||
| Q1 24 | $-42.0M | $129.0K |
| Q4 25 | $-73.0M | $-1.3M | ||
| Q3 25 | $-60.1M | $-544.0K | ||
| Q2 25 | $-65.8M | $182.0K | ||
| Q1 25 | $-64.6M | — | ||
| Q4 24 | $-50.9M | — | ||
| Q3 24 | $-44.5M | $-4.6M | ||
| Q2 24 | $-41.6M | $-2.6M | ||
| Q1 24 | $-44.8M | $-352.3K |
| Q4 25 | -537.4% | -16.9% | ||
| Q3 25 | -761.3% | -8.0% | ||
| Q2 25 | -149.4% | 2.9% | ||
| Q1 25 | -349.9% | — | ||
| Q4 24 | -382.8% | — | ||
| Q3 24 | -353.7% | -72.6% | ||
| Q2 24 | -344.4% | -40.2% | ||
| Q1 24 | -270.3% | -4.9% |
| Q4 25 | 37.8% | 0.5% | ||
| Q3 25 | 34.3% | 0.8% | ||
| Q2 25 | 6.1% | 2.6% | ||
| Q1 25 | 18.9% | — | ||
| Q4 24 | 15.8% | — | ||
| Q3 24 | 18.6% | 17.5% | ||
| Q2 24 | 16.0% | 6.5% | ||
| Q1 24 | 17.4% | 6.6% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NRIX
| Pfizer | $11.9M | 88% |
| Gilead Agreement | $1.7M | 13% |
RMCF
| Manufacturing | $5.9M | 78% |
| Transferred At Point In Time | $1.2M | 16% |
| Other | $414.0K | 5% |
